Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers. Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.
To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link
A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs. It highlights the prevalent research trends related to the year of publication, disease indications, analytical technique used for biomarker assessment, and type of cancer therapy evaluated.
The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments:
- Type of test
- Laboratory Developed Tests (LDTs)
- Companion Diagnostic Tests (CDx)
- Type of disease indication
- Breast cancer
- Blood cancer
- Colon / Colorectal cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Type of cancer biomarker
- TMB
- MSI / MMR
- TILs
- Type of analytical technique
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Others
- Key geographical regions
- North America
- Europe
- Japan
- China
- Australia
The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain:
- Foundation Medicine
- NeoGenomics Laboratories
- Novogene
- Q2 Solutions
- Personal Genome Diagnostics
- Dr Lal PathLabs
- Shenzhen Yuce Biotechnolog
Table of Contents
- Preface
2. Executive Summary - Introduction
- Current Market Landscape
- Product Competitiveness Analysis
- Company Profiles
- Publication Analysis
- Innovative Designs for Biomarker-Based Clinical Trials
- Clinical Trial Analysis
- Market Forecast
- Future Growth Opportunities
- Case Study: Analysis of Needs of Stakeholders in The Companion Diagnostics Industry
- Case Study: Analysis of Value Chain in the Companion Diagnostics Industry
- Clinical Research on Cancer Biomarkers: A Big Pharma Perspective
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi–mmr-and-tils-testing-2019–2030/253.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
